ReviewWorld journal of urology2026
Modern management of locally advanced renal cancers with inferior vena cava thrombus.
Review in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRenal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus is an uncommon but highly complex presentation associated with substantial surgical morbidity and poor natural history. This review summarises contemporary evidence on diagnostic evaluation, multidisciplinary management and operative strategies, with novel contributions on evolving minimally invasive and robotic surgical approaches, the emerging role of neoadjuvant immune checkpoint inhibition as a thrombus downstaging strategy and the inclusion of stereotactic ablative radiotherapy (SABR) in the multidisciplinary treatment pathway.
methodsA narrative review of the literature was performed, incorporating large institutional series, registry data, systematic reviews, and recent prospective and retrospective clinical studies. Evidence relating to imaging, perioperative optimisation, surgical techniques by thrombus level, decision making for cardiopulmonary bypass, neoadjuvant therapies and SABR was utilised.
resultsRadical nephrectomy with IVC thrombectomy remains the standard treatment and confers a significant survival benefit compared with non-operative management, despite perioperative mortality rates of 2-10%. Outcomes are strongly associated with tumour biology, metastatic status, and treatment at high volume centres. MRI is central for preoperative staging and prediction of operative complexity. Surgical strategy varies according to thrombus level, ranging from conventional vascular control to liver mobilisation and cardiopulmonary bypass in advanced disease. Minimally invasive approaches are increasingly becoming feasible. Neoadjuvant systemic therapy and stereotactic ablative radiotherapy show potential for thrombus downstaging yet remain investigational.
conclusionManagement requires specialised multidisciplinary care and centralisation to experienced centres. Surgery remains the cornerstone of treatment, while evolving multimodal strategies, including neoadjuvant systemic therapy and SABR, alongside improved risk stratification may further refine patient selection and outcomes.
Indexed as
Identifiers
42274802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.